Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical's GHG Emissions Data Preview
In 2024, Kobayashi Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Kobayashi Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data. b | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Verified Sources Behind Kobayashi Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kobayashi Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into Kobayashi Pharmaceutical's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Kobayashi Pharmaceutical amounted to 27,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Kobayashi Pharmaceutical increased by 12.5%, suggesting that the company faced challenges in reducing its emissions from its core operations. a b
Kobayashi Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Kobayashi Pharmaceutical's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Kobayashi Pharmaceutical were 8,000 metric tons of CO₂ equivalent (tCO₂e). a
Has Kobayashi Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Kobayashi Pharmaceutical's Scope 1 emissions have increased by 14.29%, reflecting a rising long-term trend in Scope 1 emissions over time. a
Compared to the previous year (2023), Kobayashi Pharmaceutical's Scope 1 emissions increased by 33.33%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Kobayashi Pharmaceutical's Scope 2 emissions?
In 2024, Kobayashi Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 19,000 tCO₂e without specifying the calculation method. a
What methodology does Kobayashi Pharmaceutical use for Scope 2 reporting?
In 2024, Kobayashi Pharmaceutical reported its Scope 2 emissions using an unspecified methodology. a
Kobayashi Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into Kobayashi Pharmaceutical's Value Chain Emissions
In 2024, Kobayashi Pharmaceutical reported 521,000 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of Kobayashi Pharmaceutical includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Kobayashi Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Kobayashi Pharmaceutical's Scope 3 emissions?
In 2024, Kobayashi Pharmaceutical reported total Scope 3 emissions of 521,000 metric tons of CO₂ equivalent (tCO₂e). a
Has Kobayashi Pharmaceutical reduced its Scope 3 emissions over time?
Since 2018, Kobayashi Pharmaceutical's Scope 3 emissions have decreased by 12.58%, reflecting a declining long-term trend in Scope 3 emissions over time. a
Compared to the previous year (2023), Kobayashi Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Kobayashi Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint. a
Insights into Kobayashi Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Kobayashi Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 8,000 tCO₂e and total revenues of USD 1,055 millions. This translates into an emissions intensity of 7.58 tCO₂e per millions USD. a
Kobayashi Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does Kobayashi Pharmaceutical's GHG emissions intensity compare to its peers?
In 2024, Kobayashi Pharmaceutical reported a Scope 1 emissions intensity of 7.58 tCO₂e per millions USD. Compared to the peer group median of 17.99 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does Kobayashi Pharmaceutical rank on GHG emissions intensity within its industry?
In 2024, Kobayashi Pharmaceutical ranked 8 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Kobayashi Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Kobayashi Pharmaceutical's Total Carbon Footprint
In 2024, Kobayashi Pharmaceutical reported a total carbon footprint of 548,000 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 6% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output. a b
The largest contributor to Kobayashi Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.07% of the company's total carbon footprint, followed by Scope 2 emissions at 3.47%. a